Olmesartan medoxomil treatment potently improves cardiac myosin-induced dilated cardiomyopathy via the modulation of ACE-2 and ANG 1–7 mas receptor

References

• Kodama M, Matsumoto Y, Fujiwara M, Masani F, Izumi T, Shibata A. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol 1990;57:250–262.
   PubMedGoogle Scholar
• Kodama M, Zhang S, Hanawa H, Shibata A. Immunohistochemical characterization of infiltrating mononuclear cells in the rat heart with experimental autoimmune giant cell myocarditis. Clin Exp Immunol 1992;90:330–335.
   Google Scholar
• Kodama M, Hanawa H, Saeki M, Hosono H, Inomata T, Suzuki K, Shibata A. Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res 1994;75:278–284.
   PubMed Web of Science ®Google Scholar
• Santos RA, Ferreira AJ, Simoes ESAC. Recent advances in the angiotensin-converting enzyme2-angiotensin (1–7)-mas axis. Exp Physiol 2008;93:519–527.
   PubMed Web of Science ®Google Scholar
• Igase M, Strawn WB, Gallagher PE, Geary RL, Ferrario CM. Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1–7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2005;289:H1013–H1019.
   PubMed Web of Science ®Google Scholar
• Kassiri Z, Zhong J, Guo D, Basu R, Wang X, Liu PP, et al. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail 2009;2:446–455.
   PubMed Web of Science ®Google Scholar
• Tallant EA, Clark MA. Molecular mechanisms of inhibition of vascular growth by angiotensin-(1–7). Hypertension 2007;42: 574–579.
   Google Scholar
• Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz D. Counterregulatory actions of angiotensin-(1–7). Hypertension 1997;30:535–541.
   PubMed Web of Science ®Google Scholar
• Roks AJ, van Geel PP, Pinto YM, Buikema H, Henning RH, de Zeeuw D, van Gilst WH. Angiotensin-(1–7) is a modulator of the human renin-angiotensin system. Hypertension 1999;4: 296–301.
   Google Scholar
• Zhong JC, Huang DY, Yang YM, Li YF, Liu GF, Song XH, Du K. Upregulation of angiotensin-converting enzyme 2 by all-trans retinoic acid in spontaneously hypertensive rats. Hypertension 2004;44:907–912.
   PubMed Web of Science ®Google Scholar
• Zhao YX, Yin HQ, Yu QT, Qiao Y, Dai HY, Zhang MX, . ACE-2 overexpression ameliorates left ventricular remodeling and dysfunction in a rat model of myocardial infarction. Hum Gene Ther 2010;21:1545–1554.
   PubMed Web of Science ®Google Scholar
• Tallant EA, Ferrario CM, Gallagher PE. Cardioprotective role for angiotensin-(1–7) and angiotensin converting enzyme 2 in the heart. Future Cardiol 2006;2:335–342.
   Google Scholar
• Trask AJ, Ferrario CM. Angiotensin-(1–7): pharmacology and new perspectives in cardiovascular treatments. Cardiovasc Drug Rev 2007;25:162–174.
   PubMed Web of Science ®Google Scholar
• Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, . Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1–7). Am J Physiol Heart Circ Physiol 2007;292:H736–H742.
   PubMed Web of Science ®Google Scholar
• Kaiqiang Ji, Minakawa M, Fukui K, Suzuki Y, Fukuda I. Olmesartan improves left ventricular function in pressure-overload hypertrophied rat heart by blocking angiotensin II receptor with synergic effects of upregulation of angiotensin converting enzyme 2. Ther Adv Cardiovasc Dis 2009;3: 103–111.
   PubMedGoogle Scholar
• Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 2004;43:970–976.
   PubMed Web of Science ®Google Scholar
• Sukumaran V, Veeraveedu PT, Gurusamy N, Lakshmanan AP, Yamaguchi K, Ma M, . Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1–7 mas receptor. Mol Cell Endocrinol 2012;351:208–219.
   PubMed Web of Science ®Google Scholar
• Sukumaran V, Watanabe K, Veeraveedu PT, Thandavarayan RA, Gurusamy N, Ma M, . Beneficial effects of olmesartan, an angiotensin II receptor type 1 antagonist, in rats with dilated cardiomyopathy. Exp Biol Med (Maywood) 2010;235:1338–1346.
   PubMed Web of Science ®Google Scholar
• Sukumaran V, Watanabe K, Veeraveedu PT, Gurusamy N, Ma M, Thandavarayan RA, . Olmesartan, an AT1 antagonist, attenuates oxidative stress, endoplasmic reticulum stress and cardiac inflammatory mediators in rats with heart failure induced by experimental autoimmune myocarditis. Int J Biol Sci 2011;7:154–167.
   PubMed Web of Science ®Google Scholar
• Takaya T, Kawashima S, Shinohara M, Yamashita T, Toh R, Sasaki N, . Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis 2006;186:402–410.
   PubMed Web of Science ®Google Scholar
• Watanabe E, Matsuda N, Shiga T, Kajimoto K, Ajiro Y, Kawarai H, . Significance of 8-hydroxy-2′-deoxyguanosine levels in patients with idiopathic dilated cardiomyopathy. J Card Fail 2006;12:527–532.
   PubMedGoogle Scholar
• Ashizawa N, Graf K, Do YS, Nunohiro T, Giachelli CM, Meehan WP, . Osteopontin is produced by rat cardiac fibroblasts and mediates A (II)-induced DNA synthesis and collagen gel contraction. J Clin Invest 1996;98:2218–2227.
   PubMed Web of Science ®Google Scholar
• See F, Thomas W, Way K, Tzanidis A, Kompa A, Lewis D, . p38 mitogenactivated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. J Am Coll Cardiol 2004;44:1679–1689.
   PubMed Web of Science ®Google Scholar
• Liang Q, Elson AC, Gerdes AM. p38 MAP kinase activity is correlated with angiotensin II type 1 receptor blocker-induced left ventricular reverse remodeling in spontaneously hypertensive heart failure rats. J Card Fail 2006;12:479–486.
   Google Scholar
• Machado RD, Santos RA, Andrade SP. Mechanisms of angiotensin-(1–7)-induced inhibition of angiogenesis. Am J Physiol Regul Integr Comp Physiol 2001;280:R994–R1000.
   PubMedGoogle Scholar
• da Silveira KD, Coelho FM, Vieira AT, Sachs D, Barroso LC, Costa VV, . Anti-inflammatory effects of the activation of the angiotensin-(1–7) receptor, MAS, in experimental models of arthritis. J Immunol 2010;185:5569–5576.
   Google Scholar
• Liu CX, Hu Q, Wang Y, Zhang W, Ma ZY, Feng JB, . Angiotensin-converting enzyme 2 overexpression remarkably ameliorated glomerular injury in a rat model of diabetic nephropathy: A comparison with ACE inhibition. Mol Med 2010;17:59–69.
   Google Scholar
• Bodiga S, Zhong JC, Wang W, Basu R, Lo J, Liu GC, . Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47 (phox) NADPH oxidase subunit. Cardiovasc Res 2011;91:151–161.
   Google Scholar
• Maejima Y, Okada H, Haraguchi G, Onai Y, Kosuge H, Suzuki JI, Isobe M. Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma. Lab Invest 2011;91:932–944.
   Google Scholar
• Lakshmanan AP, Watanabe K, Thandavarayan RA, Sari FR, Harima M, Giridharan VV, . Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1–7) mas receptor expression associated with its PPAR-γ agonist action. Free Radic Res 2011;45:575–584.
   PubMed Web of Science ®Google Scholar
• Mercure C, Yogi A, Callera GE, Aranha AB, Bader M, Ferreira AJ, Santos RA, Walther T, Touyz RM, Reudelhuber TL. Angiotensin (1–7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 2008;103:1319–1326.
   PubMed Web of Science ®Google Scholar
• Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX, Greenberg BH. Angiotensin-(1–7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol 2005;289: H2356–H2363.
   PubMed Web of Science ®Google Scholar
• Pan CH, Wen CH, Lin CS. Interplay of angiotensin II and angiotensin (1–7) in the regulation of matrix metalloproteinases of human cardiocytes. Exp Physiol 2008;93: 599–612.
   Google Scholar
• Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;81:1161–1172.
   PubMed Web of Science ®Google Scholar
• Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M, . Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 2010;122:717–728.
   PubMed Web of Science ®Google Scholar
• Zhong JC, Ye JY, Jin HY, Yu X, Yu HM, Zhu DL, . Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression. Regul Pept 2011;166:90–97.
   PubMedGoogle Scholar
• Koka V, Huang XR, Chung AC, Wang W, Truong LD, Lan HY. Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. Am J Pathol 2008, 172, 1174–1183.
   PubMed Web of Science ®Google Scholar
• Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1–7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol. 2005; 289:H1560–1566.
   PubMed Web of Science ®Google Scholar